€7.34m for cancer vaccine developer Having secured a €2.785m grant from the EU and €4.55m from a Series B round, MaxiVAX is going full steam ahead with its Phase II cancer vaccine programmes. more ➔
In the presence of the pHERV-W envelope protein, this interaction leads to axonal injury. The blue structures are cell nuclei. ©: HHU / Joel Gruchot / Patrick Küry GeNeuro and Karolinska Institute collaborate in multiple sclerosisGeneva-based GeNeuro SA announced a new clinical study of temelimab to treat patients with multiple sclerosis in collaboration with Karolinska Institute and ASC. more ➔
Tecentriq-Avastin combo hits endpoint in liver cancerRoche AG said on Friday that its PD-L1 blocker Tecentriq plus its VEFG blocker Avastin improved progression-free survival versus sorafinib in a pivotal study in hepatocellular carcinoma (HCC) patien … more ➔
Azeria Therapeutics bags €37.3m in Series B financing roundAzeria Therapeutics Ltd (Cambridge, UK) has raised a £32m (€37.3m) in a Series B financing led by Syncona Ltd contributing £29.5m (€34.4m). more ➔
GHO capital launches EU’s largest fund ever for life sciencesGHO Capital raises €975m in largest ever European private equity healthcare fund. more ➔
Update: BIO-Europe growing furtherEurope’s largest partnering event, the BIO-Europe, hit another visitor record on the occasion of its 25th anniversary in Hamburg. more ➔
Zelluna Immunotherapy and Glycostem Therapeutics in licence dealZelluna Immunotherapy and Glycostem Therapeutics have partnered to develop allogeneic TCR-NK therapies. more ➔
Novo secures Dicerna’s RNAi liver assetsDanish Novo Nordisk A/S has secured access to Dicerna Inc’s GalXC RNAi technology in a R&D deal worth US$225m upfront over three years comprising 30 liver targets. more ➔
EU with poor success in fighting superbugs The EU has made poor progress combatting antimicrobial resistance, a report from the European Court of Auditors (ECA) warns. Innovators need to be supported, urges the BEAM Alliance. more ➔
Cellectis presents way to safer CAR-TsResearchers at French-US allogeneic CAR-T cell developer Cellectis SA have designed an engineered CAR-T cell that secretes IL-12 upon contact with tumour cells. more ➔
In the presence of the pHERV-W envelope protein, this interaction leads to axonal injury. The blue structures are cell nuclei. ©: HHU / Joel Gruchot / Patrick Küry
